Journal
FRONTIERS IN AGING NEUROSCIENCE
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnagi.2021.654978
Keywords
Alzheimer's disease; miRNAs; lncRNAs; piRNAs; circRNAs
Categories
Funding
- National Natural Science Foundation of China [81901085]
- China Postdoctoral Science Foundation [2019M662302]
- Qingdao Applied Basic Research Project [19-6-2-50-cg]
Ask authors/readers for more resources
Alzheimer's disease, a progressive neurodegenerative disorder, is characterized by the involvement of non-coding RNAs, which may serve as potential therapeutic targets and biomarkers for discovering novel treatments.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder. AD is characterized by the production and aggregation of beta-amyloid (A beta) peptides, hyperphosphorylated tau proteins that form neurofibrillary tangles (NFTs), and subsequent neuroinflammation, synaptic dysfunction, autophagy and oxidative stress. Non-coding RNAs (ncRNAs) can be used as potential therapeutic targets and biomarkers due to their vital regulatory roles in multiple biological processes involved in disease development. The involvement of ncRNAs in the pathogenesis of AD has been increasingly recognized. Here, we review the ncRNAs implicated in AD and elaborate on their main regulatory pathways, which might have contributions for discovering novel therapeutic targets and drugs for AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
